FORE Biotherapeutics Secures Breakthrough Therapy Status for Plixorafenib
Thursday, April 02, 2026
FORE Biotherapeutics has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for plixorafenib, a targeted therapy for adult patients with BRAF V600E-mutated high-grade glioma.
High-grade glioma is an aggressive form of brain tumour associated with poor outcomes and limited treatment options. Plixorafenib is a novel BRAF inhibitor designed to selectively target BRAF alterations and disrupt tumour growth.
The designation is based on clinical data from around 25 patients enrolled in an early-stage Phase 1/2a trial, along with ongoing results from the Phase 2 FORTE basket study. The FORTE trial is evaluating the therapy across a range of BRAF-mutated central nervous system tumours, including both high-grade and low-grade gliomas, as well as other primary brain and spinal cord cancers in adults and children.
Breakthrough Therapy Designation is granted to medicines intended to treat serious or life-threatening conditions where early clinical evidence indicates meaningful improvement over existing treatments. The status provides closer interaction with the regulator and may enable faster development and review.
Clinical findings from earlier studies showed encouraging anti-tumour activity in patients with BRAF V600-mutated primary CNS tumours, including a notable response rate in a defined subgroup. The ongoing FORTE study has met interim analysis criteria, with independent review supporting its continuation.
Plixorafenib has also received Fast Track and Orphan Drug designations for the treatment of BRAF-altered cancers and primary brain tumours. These regulatory supports aim to accelerate the development of the therapy as further clinical data becomes available.
Source: businesswire.com
